Auris Medical Announces Launch of New Corporate Website
16 juil. 2021 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, July 15, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection,...
Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2
14 juil. 2021 09h00 HE
|
Auris Medical AG
Bentrio™ formulation well tolerated in vitro on human nasal epitheliumUp to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controlsViral titer reduced 12- or 14-fold vs....
Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology
06 juil. 2021 09h00 HE
|
Auris Medical AG
Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platformCompany to launch development program under project code AM-401 with aim of IND submission...
Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany
28 juin 2021 08h30 HE
|
Auris Medical AG
Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection,...
Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma
21 juin 2021 08h30 HE
|
Auris Medical AG
Treatment with OligoPhoreTM siRNA stops aggressive ATLL tumor growth to near zeroSignificant reduction in tumor size, spleen size and peripheral blood lymphocyte countsResults add to extensive body of...
Auris Medical Announces Acquisition of RNA Therapeutics Company and Plans for Strategic Repositioning
03 juin 2021 07h30 HE
|
Auris Medical AG
Entering field of RNA therapeutics through acquisition of Trasir Therapeutics, Inc.Trasir’s innovative peptide-based OligoPhoreTM platform designed to enable extrahepatic delivery of...
Auris Medical Starts Preparations for Covid-19 Trial with Bentrio in India
01 juin 2021 08h30 HE
|
Auris Medical AG
Hamilton, Bermuda, June 1, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...
Auris Medical Holding to Present at LD Micro Invitational XI Conference
28 mai 2021 08h30 HE
|
Auris Medical AG
Hamilton, Bermuda, May 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...
Auris Medical Announces Completion of Bentrio Conformity Assessment Procedure for Marketing in EU
25 mai 2021 09h00 HE
|
Auris Medical AG
Meeting essential requirements for marketing BentrioTM in Europe under CE markOn track for first product launch in Europe towards end of Q2 2021 Hamilton, Bermuda, May 25, 2021 – Auris Medical...
Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo
14 mai 2021 08h30 HE
|
Auris Medical AG
Hamilton, Bermuda, May 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...